Forte Biosciences posts Q3 2025 results release

Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is included as Exhibit 99.1 to the report.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Forte Biosciences (FBRX) disclose in this 8-K filing?

Forte Biosciences disclosed that it issued a press release reporting its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is attached to the filing as Exhibit 99.1 for investor reference.

Which period’s results are covered in Forte Biosciences (FBRX) press release?

The press release covers Forte Biosciences’ financial results for the quarter ended September 30, 2025. This period information is highlighted in the filing, with the related press release furnished as Exhibit 99.1 rather than formally filed under the Exchange Act.

How is the Forte Biosciences (FBRX) earnings press release treated under SEC rules?

The earnings press release is furnished, not filed, under Item 2.02 of the Exchange Act. The filing states it will not be deemed filed for Section 18 liability or automatically incorporated into Securities Act or Exchange Act filings unless specifically referenced.

What exhibits are included with Forte Biosciences (FBRX) November 14, 2025 8-K?

The filing includes Exhibit 99.1, a press release dated November 14, 2025, reporting quarterly financial results, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document, which supports electronic reporting requirements for the 8-K.

Who signed the November 14, 2025 Forte Biosciences (FBRX) 8-K?

The 8-K was signed on behalf of Forte Biosciences, Inc. by Antony Riley, the company’s Chief Financial Officer. The signature block confirms that the registrant caused the report to be signed by this duly authorized officer on November 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 09:05 AM EST Learn about SEC filing dates

false 0001419041 0001419041 2025-11-14 2025-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

FORTE BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38052		26-1243872
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3060 Pegasus Park Dr. Building 6 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (310) 618-6994

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		FBRX		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 14, 2025, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release dated November 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				FORTE BIOSCIENCES, INC.
Date: November 14, 2025				By:		/s/ Antony Riley
						Antony Riley Chief Financial Officer